Clinical Trial Update: Anti CD19/BCMA CAR Gene Therapy for Relapsed/Refractory Immune Thrombocytopenia [NA]

View source ↗

Summary

A clinical trial evaluating an anti-CD19/BCMA CAR T-cell therapy for relapsed/refractory immune thrombocytopenia is currently recruiting at Anhui Provincial Hos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Anti-CD19/BCMA CAR T cell therapy (CD19/BCMA CAR-T)

Snippet

Sponsor: Anhui Provincial Hospital | Conditions: Immune Thrombocytopenia (ITP) | NA | Status: RECRUITING